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Abstract  
 
Objective: Cardiac disease is the leading cause of indirect maternal mortality. The aim of this study was to 
analyse to what extent socioeconomic factors influence the outcome of pregnancy in women with heart 
disease.  
Methods: The Registry Of Pregnancy And Cardiac disease (ROPAC) is a global prospective registry. For this 
analysis, countries that enrolled ≥10 patients were included. A combined cardiac endpoint included maternal 
cardiac death, arrhythmia requiring treatment, heart failure, thromboembolic event, aortic dissection, 
endocarditis, acute coronary syndrome, hospitalisation for cardiac reason or intervention. Associations 
between patient characteristics, country characteristics (income inequality expressed as Gini-coefficient, 
health expenditure, schooling, gross domestic product, birth rate, and hospital beds) and cardiac endpoints 
were checked in a three-level model (patient-centre-country). 
Results: A total of 30 countries enrolled 2924 patients from 89 centres. At least one endpoint occurred in 645 
women (22.1%). Maternal age, New York Heart Association, and modified World Health Organization risk 
classification, were associated with the combined endpoint and explained 37% of variance in outcome. Gini-
coefficient and country-specific birth rate explained an additional 4%. There were large differences between 
the individual countries, but the need for multilevel modelling to account for these differences disappeared 
after adjustment for patient characteristics, Gini and country specific-birth rate. 
Conclusion: While there are definite interregional differences in pregnancy outcome in women with cardiac 
disease, these differences seem to be mainly driven by individual patient characteristics. Adjustment for 
country characteristics refined the results to a limited extent, but maternal condition seems to be the main 
determinant of outcome. 
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 What is already known about this subject? 
Previous studies have shown that human development index is a strong predictor of maternal and 
fetal mortality rate in the global population. Inequality of socioeconomic circumstances, lower 
educational level and lower human development index have been reported to be associated with 
maternal adverse outcome.  
 What does this study add?  
To what extent these correlations can be extrapolated to women with pre-existent cardiac disease, 
has not been determined until now. The Registry Of Pregnancy And Cardiac disease (ROPAC) is the 
largest recorded cohort of pregnant women with cardiac disease. The current study shows that 
differences in outcome between centres and countries are largely explained by differences in 
individual patient characteristics, such as NYHA classification, prior signs of heart failure and modified 
WHO classification.  
 How might this impact on clinical practice? 
Socioeconomic factors were partly explainable for differences in pregnancy outcome in women with 
cardiac disease, but the main denominator was the individual’s condition. Raising awareness and 
improving access to medical resources as advocated by the World Health Organization, will help to 
improve the outcome for pregnant women, hopefully also for women with heart disease. 
  
   
Introduction 
Cardiac disease is an important cause of maternal mortality and morbidity. Recent data from the Global 
Burden of Disease study has demonstrated that geographical disparities widened between 1990 and 2015 and 
that in 2015, 24 countries still had a maternal mortality ratio greater than 400 per 100 000. Those recent data 
have shown that overall maternal mortality pattern is influenced by Socio-Demographic index (SDI) with 
women in the highest SDI quintile dying frequently due to indirect maternal disorders as cardiovascular and 
thrombotic disease[1, 2]. The Registry Of Pregnancy And Cardiac disease (ROPAC) is a global cohort including 
pregnant patients from both advanced and emerging countries. Several analyses from ROPAC data have been 
published with marked differences between advanced and emerging countries[3, 4, 5]. These differences could 
be partly explained by variations in underlying cardiac condition, with acquired valvular disease being more 
prevalent in emerging countries[6] and congenital heart disease in advanced countries. In addition, the 
demographic differences may also influence outcome. For instance, in some cultures women gain status by 
having (many) children and thus they may be reluctant to take a doctor’s advice to avoid pregnancy. Also, 
there is widespread difference in the availability of health care and access to female contraception. Although 
tertiary care is provided in the urban areas, many women in less developed countries are from rural areas and, 
consequently, might present with pregnancy complaints much later than their peers from rural areas in 
countries with more advanced economies[7]. 
Interpretation of ROPAC results needs to be done with caution in the light of these differences. Insights in 
country level socioeconomic data and the associated pregnancy outcomes will help interpreting existing and 
future analyses. Such an analysis could define the influence of socioeconomic background on pregnancy 
outcome exerted by the countries of residence, the alternative approach, of an in depth analysis of individual 
socioeconomic data, is not possible. 
The aim of this study was to elucidate the interregional differences in the countries contributing to ROPAC, by 
analysing to what extent socioeconomic factors on country level,  such as gross domestic product, income 
distribution/inequality (Gini-coefficient), HDI, health expenditure, birth rate, number of hospital beds and 
schooling, influence the outcome of pregnancy in women with heart disease. We hypothesized that country 
   
level socioeconomic indices do influence pregnancy outcome and that cardiac status (such as severity of 
disease and NYHA) affects the outcome of mother and baby to a greater extent.   
Methods 
The Registry Of Pregnancy And Cardiac disease (ROPAC) is an ongoing prospective worldwide registry that 
includes all consecutive pregnant women with structural heart disease. Study design and methods have been 
described in detail previously[3]. Patient enrollment started from January 2008 and for this interim analysis we 
included patients with a term date up to October 2013, and 6 months follow-up in April 2014. Patient 
informed consent was obtained when required by the local independent review board. Patients with either 
congenital, valvular or ischemic heart disease, a cardiomyopathy, pulmonary hypertension, aortic pathology 
were included. Women with non-structural disease such as arrhythmia were excluded. More specific details on 
disease have been published previously [3, 8]. 
Data  
The patient characteristics collected at baseline (before pregnancy) included age, ECG rhythm, New York Heart 
Association (NYHA) functional classification, diagnosis, risk factors for cardiovascular disease (smoking, 
diabetes, hypertension), previous interventions, medication, parity, obstetric history and if available 
echocardiographic parameters. Every patient was stratified according to the modified World Health 
Organization (WHO) classification, as stated in the latest guidelines[9, 10] by two authors (IH;JRH). Modified 
WHO-class I implies no increased risk of events during pregnancy, compared to the general pregnant 
population. Modified WHO-class II has a small increased risk, class II-III a moderate increased risk, and class III 
has a ‘significantly’ increased risk. Class IV bears an unacceptable high risk of complications and consensus 
suggests that pregnancy should be avoided. 
For the current study, pre-pregnancy patient characteristics that were included in statistical modelling were 
age, nulliparity, modified WHO class, NYHA class and signs of heart failure. 
Socioeconomic data on patient level were not available. As a result, pre-defined socioeconomic factors were 
assigned to represent country characteristics, and included: human development index (HDI), Gini-coefficient, 
health expenditure, schooling, gross domestic product per capita based on purchasing power parity (GDP), 
   
birth rate per 1,000, and hospital beds per 1,000. Definitions and sources of these characteristics are listed in 
Supplementary Material Appendix 1. HDI is a combination of three factors; life expectancy from birth, mean 
years of schooling and the country standard of living.  As these factors correlate with the other predefined 
country characteristics, the HDI was not included in further modelling. The HDI categories (low, medium, high, 
very high) were only used to categorize and understand the frequency of events within the different 
categories.  
Endpoints  
The following endpoints that occurred up to one week after delivery were studied: combined cardiac endpoint 
(including maternal cardiac death, arrhythmia requiring treatment, heart failure, thromboembolic event, aortic 
dissection, endocarditis, acute coronary syndrome, hospitalisation for cardiac reason, or a cardiac 
intervention), heart failure, fetal or neonatal mortality (excluding miscarriage in the first trimester), and small-
for-gestational-age (SGA, birth weight <10th percentile). All-cause mortality data was also collected, but not 
used for statistical modelling due to low numbers. Heart failure was defined according to ACC/AHA 
guidelines[11], as a clinical syndrome that is characterised by specific symptoms (dyspnea and fatigue) and 
signs (of fluid retention, such as oedema, rales) on the physical examination as judged by the treating 
cardiologist. The heart failure episode was only registered when signs or symptoms of HF were present which 
required new treatment, change of treatment or hospital admission. 
Statistical analysis 
Categorical variable differences were tested using chi-square tests and are presented as percentages; in case 
of 3 categories Pearson chi square tests were performed. Continuous variables are presented as mean and 
standard deviation (SD), or as median and first and third quartile (Q1-Q3), as appropriate. Differences were 
tested using Student’s t-tests; in case of 3 categories  one-way ANOVA tests were performed. 
Generalized linear mixed models (GLMM) were used as a result of the multilevel structure in the data. The  
ROPAC database consists of three levels: patients (level 1) were nested in centres (level 2), and centres were 
nested in countries (level 3). To account for differences in outcome between countries and between centres, 
random effects for country and centre were added to the model. Patient and country characteristics were 
   
entered as fixed effects and those with a significant trend (p<0.10) in univariable analysis were assessed in 
multivariable analysis. Countries that included less than 10 patients were excluded from this study.  
To determine the influence of fixed and random effects in our cohort, we further analysed the model for the 
combined cardiac endpoint. A conditional R2 (for GLMM) was derived from the model before and after 
including the fixed effects (patient characteristics, followed by country characteristics) [12]. This is an estimate 
of the percentage explained variance by the complete model (fixed and random effects). The random effect 
estimates of the individual countries for the combined cardiac endpoint were plotted with 95% confidence 
intervals (caterpillar plot), unadjusted and adjusted for the fixed effects.   
The rate of missing patient and country characteristics was relatively low, and therefore a complete case 
analysis approach was taken (96%). All analyses, except for multilevel modelling, were performed in SPSS 
version 21.0 (IBM Corp., Armonk, NY). Multilevel modelling was performed in R version 3.1, package lme4 [13]. 
 
Results 
From January 2008 until April 2014, 2966 patients were included, from 99 centres in 39 countries. Nine 
countries enrolled less than 10 patients, and were excluded. The remaining 30 countries enrolled 2924 
patients from 89 centres. An overview of the countries is presented and arranged according to the HDI 
categories in Table 1. Socioeconomic indexes, including HDI, Gini coefficient, health expenditure, schooling, 
GDP, birth rate per 1,000 and hospital beds per 1,000 are presented for all countries in Supplemental material 
Table S1. 
Baseline characteristics are presented for patients per HDI category (Table 2). Maternal age at conception was 
higher in women from countries with a very high HDI, while these women were also more often nulliparous. 
Fewer women from countries with a medium or high HDI had a prior cardiac intervention and were in NYHA 
class I, compared to women from countries with a very high HDI. Indeed, signs of heart failure prior to 
pregnancy were more common; cardiac medication, mainly diuretics, were more commonly used before 
pregnancy by women from countries with a medium or high HDI compared to those from countries with a very 
high HDI. Valvular heart disease was much more common in women from countries with a medium HDI, while 
women from countries with a high or very high HDI more often had congenital heart disease. 
   
Women with modified WHO class III or IV more often came from countries with a medium or high HDI, while 
women with a lower risk WHO class more often came from countries with a very high HDI. 
Table 1 Human development index categories 
 
  Low Medium  High Very high 
Human development index* <0.555 0.555-0.699 0.700-0.799 ≥0.800 
  (n=634) (n=118) (n=2130) 
Countries in ROPAC  Egypt Azerbaijan Argentina 
  South-Africa Russian Federation Australia 
    Austria 
    Belgium 
    Canada 
    Czech Republic 
    France 
    Greece 
    Germany 
    Hungary 
    Italy 
    Japan 
    Lithuania 
    Israel 
    Malta 
    Netherlands 
    Norway 
    Poland 
    Portugal 
    Slovenia 
    Spain 
    Sweden 
    Switzerland 
    United Arab Emirates 
    United Kingdom 
    United States 
     
  <10 patients per country <10 patients per country <10 patients per country 
   Brazil Ireland 
   Bulgaria  
   Georgia  
   Macedonia  
   Romania  
   Serbia&Montenegro  
   Turkey  
          
*Human development index for female according to United Nations Development Report 2013. No value was available for 
Bosnia&Herzegovina (<10 inclusions) 
 
   
Table 2 Baseline characteristics 
 Total* Low HDI Medium HDI High HDI Very High HDI p 
N (% of total inclusions) 2966   0 634 21.7% 118 4.0% 2172 74.3%   
            
Mean age (sd) 29.3 ±5.6   27.7 ±5.9 26.4 ±5.3 29.9 ±5.4 <0.001 
Nulliparous  1334 45.2%   160 25.2% 57 48.3% 1099 50.7% <0.001 
Pre-existent hypertension  188 6.5%   26 4.1% 18 16.2% 139 6.5% <0.001 
Current smoker  110 4.3%   11 1.8% 4 3.6% 95 5.3% 0.001 
Pre-existent diabetes  46 1.6%   10 1.6% 1 0.8% 34 1.6% 1.000 
Prior cardiac intervention  1585 53.6%   223 35.2% 44 37.3% 1304 60.1% <0.001 
            
NYHA functional class           <0.001 
NYHA I 2154 74.1%   399 62.9% 48 42.1% 1686 79.3%  
NYHA II 659 22.7%   191 30.1% 62 54.4% 395 18.6%  
NYHA III 86 3.0%   42 6.6% 4 3.5% 39 1.8%  
NYHA IV 7 0.2%   2 0.3% 0 0.0% 5 0.2%  
            
Signs of HF before pregnancy  283 9.7%   138 21.8% 66 58.4% 74 3.5% <0.001 
AF before pregnancy  68 2.3%   47 7.4% 1 0.9% 20 0.9% <0.001 
            
Prior medication 824 27.9%   292 46.1% 17 14.4% 510 23.5% <0.001 
Beta-blocker 365 12.3%   75 11.8% 7 5.9% 280 12.9% 0.073 
Anti-arrhythmic 90 3.0%   58 9.1% 3 2.6% 28 1.3% <0.001 
ACE-inhibitor 116 3.9%   38 6.0% 9 7.6% 67 3.1% 0.001 
Diuretic  170 5.8%   93 14.7% 7 5.9% 68 3.1% <0.001 
            
Cardiac diagnosis           <0.001 
Congenital heart disease 1654 55.9%   88 13.9% 91 77.1% 1458 67.1%  
Valvular heart disease 942 31.8%   489 77.1% 15 12.7% 424 19.5%  
Ischemic heart disease 47 1.6%   7 1.1% 0 0.0% 40 1.8%  
Cardiomyopathy 201 6.8%   45 7.1% 4 3.4% 151 7.0%  
Aortic pathology 101 3.4%   3 0.5% 6 5.1% 90 4.1%  
Pulmonary hypertension 13 0.4%   2 0.3% 2 1.7% 9 0.4%  
            
WHO classification           <0.001 
WHO class I 583 19.7%   73 11.5% 27 22.9% 474 21.8%  
WHO class II 520 17.6%   18 2.8% 17 14.4% 481 22.1%  
WHO class II-III 932 31.5%   150 23.7% 34 28.8% 735 33.8%  
WHO class III 486 16.4%   187 29.5% 8 6.8% 286 13.2%  
WHO class IV 437 14.8%   206 32.5% 32 27.1% 196 9.0%   
Percentages are of total valid cases, excluding missing cases.*Total cohort includes countries with less than 10 patients. ACE = Angiotensin Receptor Enzym; AF = Atrial 
fibrillation; HDI = Human development index; HF = Heart failure; NYHA = New York Heart Association; WHO = World Health Organization. 
 
  
   
Frequency of endpoints 
Clinical event rates are presented for each HDI group (Figure 1) and for all countries separately (Table 3). A 
combined cardiac endpoint occurred in 645 women (22.1%); heart failure in 365 (12.5%);  fetal/neonatal loss 
in 60 (2.1%); small-for-gestational age in 270 (10.6%). Maternal mortality up to one week postpartum occurred 
in 11 cases (0.9% medium HDI, 0.8% high HDI, and 0.2% very high HDI, p=0.016) and was not included in the 
univariable or multivariable analysis.  
 
Associations of patient and country characteristics with clinical endpoints 
Univariable analysis of pre-pregnancy patient characteristics for the combined cardiac endpoint is shown in 
Table 4. The only variable that was not significantly associated with the combined cardiac endpoint was 
nulliparity.  Modified WHO II was not significantly different from modified WHO I. Of the country 
characteristics, Gini coefficient (p=0.017) and birth rate (although p=0.050) were independently associated 
with the combined cardiac endpoint, in addition to age, NYHA class, modified WHO class and signs of heart 
failure before pregnancy.  
The univariable and multivariable analysis of the remaining endpoints are shown in the online supplemental 
data. The results for heart failure as a separate endpoint were largely comparable to the results of the 
combined cardiac endpoint (online supplemental Table S2). While schooling, GDP, birth rate and number of 
hospital beds were associated with fetal/neonatal mortality in the univariable analysis, only GDP was 
independently associated with this endpoint (online supplemental Table S3). None of the country 
characteristics were associated with SGA, on top of NYHA II and III, and modified WHO class III and IV (online 
supplemental Table S4).  
 
Influence of variability between countries and centres 
The total explained variability of the model, the conditional R2, for the combined cardiac endpoint including 
patient characteristics only, was 37%. By adding the country characteristics, the R2 increased by 4% to 41%. 
Without any of these fixed effects in the model the conditional R2  including random effects only, was 33%. 
Figure 2 depicts the estimated unadjusted and adjusted odds ratios for a combined cardiac endpoint for each 
country compared to the average odds ratio.  Several countries do not include the 0 in their 95% confidence 
   
interval in the unadjusted model. But when adjusted for patient and country characteristics, the 95% 
confidence intervals of almost all countries do include 0. This means that for the vast majority of the countries, 
the need to account for random effects (patient within centre, within country) disappears when adjusting for 
patient and country characteristics. 
   
Table 3 Events per country 
  
Maternal mortality  
(all cause)  Heart failure Combined cardiac endpoint 
Fetal/neonatal mortality (no 
miscarriage) Small for gestational age 
  total n n % n %   n %   n % n %   
               
ARGENTINA 
10 0 0,0% 0 0,0%  0 0,0%  0 0,0% 1 10,0%  
AUSTRALIA 
19 0 0,0% 2 10,5%  4 21,1%  0 0,0% 2 10,5%  
AUSTRIA 
83 0 0,0% 1 1,2%  4 4,8%  1 1,2% 1 1,2%  
AZERBAIJAN 
10 0 0,0% 2 20,0%  2 20,0%  0 0,0% 0 0,0%  
BELGIUM 
125 0 0,0% 2 1,6%  5 4,0%  0 0,0% 3 2,4%  
CANADA 
57 1 1,8% 3 5,3%  6 10,5%  2 3,5% 2 3,5%  
CZECH REPUBLIC 
14 0 0,0% 0 0,0%  0 0,0%  0 0,0% 1 7,1%  
EGYPT 
573 6 1,0% 120 20,9%  
198 34,6%  31 5,4% 30 5,2%  
FRANCE 
58 0 0,0% 13 22,4%  
26 44,8%  0 0,0% 10 17,2%  
GERMANY 
229 0 0,0% 3 1,3%  
10 4,4%  1 0,4% 23 10,0%  
GREECE 
27 0 0,0% 3 11,1%  
11 40,7%  0 0,0% 6 22,2%  
HUNGARY 
44 0 0,0% 0 0,0%  1 2,3%  1 2,3% 4 9,1%  
ISRAEL 
61 0 0,0% 19 31,1%  25 41,0%  1 1,6% 7 11,5%  
ITALY 
238 1 0,4% 12 5,0%  33 13,9%  3 1,3% 28 11,8%  
JAPAN 
33 0 0,0% 2 6,1%  2 6,1%  0 0,0% 6 18,2%  
LITHUANIA 
60 0 0,0% 5 8,3%  5 8,3%  1 1,7% 8 13,3%  
MALTA 
19 0 0,0% 0 0,0%  
1 5,3%  0 0,0% 2 10,5%  
NETHERLANDS 
299 0 0,0% 9 3,0%  38 12,7%  2 0,7% 23 7,7%  
NORWAY 
28 0 0,0% 4 14,3%  6 21,4%  0 0,0% 1 3,6%  
POLAND 
113 0 0,0% 11 9,7%  27 23,9%  3 2,7% 13 11,5%  
PORTUGAL 
13 0 0,0% 0 0,0%  0 0,0%  1 7,7% 0 0,0%  
RUSSIAN FEDERATION 
108 1 0,9% 57 52,8%  
90 83,3%  0 0,0% 13 12,0%  
SLOVENIA 
128 0 0,0% 2 1,6%  10 7,8%  3 2,3% 12 9,4%  
SOUTH AFRICA 
61 0 0,0% 30 49,2%  34 55,7%  5 8,2% 8 13,1%  
SPAIN 
221 1 0,5% 20 9,0%  32 14,5%  3 1,4% 29 13,1%  
   
SWEDEN 
33 0 0,0% 5 15,2%  7 21,2%  1 3,0% 6 18,2%  
SWITZERLAND 
45 0 0,0% 2 4,4%  5 11,1%  0 0,0% 5 11,1%  
UNITED ARAB EMIRATES 
31 0 0,0% 13 41,9%  16 51,6%  0 0,0% 5 16,1%  
UNITED KINGDOM 
120 1 0,8% 16 13,3%  31 25,8%  0 0,0% 15 12,5%  
UNITED STATES 
64 0 0,0% 9 14,1%   16 25,0%   1 1,6% 6 9,4%    
  
    
 
       
TOTAL 
2924 11 0,4% 365 12,5%  645 22,1%  60 2,1% 270 9,2%  
  
   
Table 4 Univariable and multivariable analysis of patient and country characteristics with the combined cardiac 
endpoint 
 
 Univariable Multivariable  
Variable OR 95% CI   OR 95% CI 
Age 1.026 1.008 − 1.045  1.020 1.000 − 1.039 
Nulliparity 0.955 0.777 − 1.174    
 
 
NYHA I NA     NA    
NYHA II 2.735 2.179 − 3.434  1.944 1.487 − 2.541 
NYHA III 9.18 5.435 − 15.506  3.062 1.657 − 5.658 
NYHA IV 26.01 2.634 − 256.826  7.456 0.792 − 70.209 
WHO I NA     NA    
WHO II 1.088 0.689 − 1.719  0.997 0.618 − 1.607 
WHO II-III 2.261 1.575 − 3.246  1.992 1.371 − 2.895 
WHO III 4.351 2.947 − 6.426  3.862 2.586 − 5.767 
WHO IV 8.383 5.67 − 12.394  4.954 3.238 − 7.578 
Signs of heart failure 4.165 3.037 − 5.711  1.708 1.167 − 2.502 
 
    
   
 
 
Gini* 1.706 1.266 − 2.297  1.393 1.06 − 1.831 
Health expenditure* 0.739 0.463 − 1.178    
 
 
Schooling* 0.965 0.468 − 1.991    
 
 
GDP* 0.737 0.453 − 1.200      
Birth Rate* 2.896 1.742 − 4.815  1.622 1.001 − 2.629 
Hospital beds* 0.708 0.446 − 1.123    
 
 
                    
Data are clustered within hospitals within countries. The categorical variable NYHA classification and WHO are tested against 
the reference category I. WHO II is not significantly different from WHO I. The only variable that is not significant is nulliparity.  
GDP = Gross domestic product, NYHA = New York Heart Association, WHO = World Health Organization 
*Numerical data were standardized before analysis 
 
Discussion 
The ROPAC registry is the largest recorded cohort of pregnant women with cardiac disease. Women from 
many different countries were included. Results may be influenced by the multicenter and multinational 
nature of the registry. The current study shows that indeed there are differences in outcome between centres 
and countries, but these differences are largely explained by differences in individual patient characteristics, 
such as NYHA classification, prior signs of heart failure and modified WHO classification. Only a few country 
characteristics had some impact: maternal cardiac event was associated with Gini coefficient and to a lesser 
extent with birth rate of the patients’ residential country. Also fetal outcome, such as small for gestational age 
was mainly associated with the maternal condition and to a minor extent with country characteristics.  
   
Maternal outcome and socioeconomic influences 
Previous studies have shown that human development index is a strong predictor of maternal and fetal 
mortality rate in the global population[14]. Inequality of socioeconomic determinants within a country further 
increases the rate of maternal death[15]. A lower educational level and lower HDI have been reported to be 
associated with maternal adverse outcome[16]. Less educated women, for instance, have an increased risk of 
presenting to an emergency department in a severe condition[17]. This may be related to several issues: 
women from emerging countries tend to have a later presentation to a medical centre, which is probably 
associated with limited knowledge and awareness of risks and lack of money, but also to factors like a less well 
developed infrastructure, longer travel-time and perhaps less availability of skilled medical staff. To what 
extent these correlations can be extrapolated to women with pre-existent cardiac disease, and whether they 
need to be taken into account while analysing multinational registry data, has not been determined until now. 
Although the number of maternal deaths was too low to allow for statistical analysis, the risk of a cardiac 
event (combined endpoint) was indeed associated with income inequality (expressed as the Gini-coefficient)  
in a country. Also, a higher country birth rate correlated with a higher frequency of heart failure. These 
socioeconomic parameters need to be considered when interpreting data from registries, however, we feel 
that the number of factors actually showing a relationship to pregnancy outcome in these high risk patients, is 
actually relatively small compared to their impact in the general pregnant population. In fact, the most 
important determinant of pregnancy outcome was the underlying medical condition. 
This cohort consists of a rather large subgroup of women with a cardiac condition considered modified WHO 
group 3 and 4. Category 4 involves women who should rather be advised to avoid pregnancy. However, in the 
end, the woman will decide herself whether she will proceed to try and get pregnant, and of course clinical 
care will not be denied to this group of women. Whether this group involves women who were not 
appropriately counseled about their risks following the latest guidelines, may also be subject to further 
discussion. The fact that a greater part of women from less well developed countries were in a higher modified 
WHO category (3 or 4), has undoubtedly influenced the outcome of our study. While the underlying disease is 
   
a given fact, availability of good preconception, perinatal and maternal care certainly deserves attention. It is 
part of the United Nations Millennium Goals, and this study emphasizes the need for improvement of care. 
 
Fetal outcome 
With regard to fetal and obstetric outcome, previous reports showed that a higher income inequality (Gini 
coefficient) and educational level, rather than household income, seem to be associated with intrauterine 
growth but not with shorter gestational age at delivery[18, 19].  The exact underlying mechanism is difficult to 
determine. A recent large prospective cohort study of pregnant women showed that women from low 
socioeconomic subgroups have higher placental resistance indices, which may be explained by smoking. This 
association may contribute to a higher incidence of pregnancy complications and even stillbirth[20, 21].  
In our cohort of women with cardiac disease, country characteristics did not significantly influence the SGA 
rate, while maternal condition expressed as NYHA class and modified WHO classification did influence the 
frequency of SGA. In women with reduced cardiac function, an abnormal uteroplacental flow is present, which 
is an important predictor of adverse obstetric and fetal outcome[22] and this may explain the association in 
this study.  
Research and clinical implications  
The results imply that interregional differences need to be acknowledged, also in research, but that the 
maternal condition seems to outweigh the influence of socioeconomic factors on reported cardiac and fetal 
outcome. A clear association between socioeconomic factors and events was present in univariable analysis, 
but it largely disappeared after correction for maternal condition. Thus, the higher event rate in emerging 
compared to advanced countries is mainly based on a worse pre-pregnancy condition of patients. Also, the 
need for multilevel modelling in this analysis was lost after adding the patient and country characteristics.  
Data on cultural background were lacking, but would be very interesting to study. Differences in pregnancy 
outcome between emerging and advanced countries, may be related to for instance religion. Women may 
have a strong feeling that their fate is predetermined and therefore less sensible to a doctor’s advice. But this 
   
hypothesis is rather philosophical and needs further investigation to determine whether this indeed influences 
pregnancy outcome. 
Reducing adverse pregnancy outcome in any region, but in particular in remote areas, is an important goal as 
formulated by the WHO. While this goal resulted in major declines in maternal death rates globally, this trend 
has definitely not been observed in maternal death due to cardiac disease[23]. Creating awareness in young 
women with cardiac disease about the potential high risks of pregnancy should be part of standard care and 
preferably initiated at a young age. The fifth  millennium goal of the World Health Organization is reduction of 
maternal mortality, by means of increasing the number of women receiving at least 4 antenatal care visits and 
the number of births attended by skilled staff[24]. An increase in the number of women receiving this level of 
care and a decline in maternal death rate has been observed in the past 10-15 years, but about 50% of women 
still do not receive the recommended minimum of four antenatal visits. Also, a well-developed infrastructure 
for cardiovascular health screening is warranted to ensure early diagnosis and management[25]. 
Improvements in these medical resources may also reduce the burden of adverse events in pregnant women 
with cardiac disease. 
Other global observational studies, for instance those dealing with factors influencing secondary 
cardiovascular prevention, did find related socio-economic factors. One study pointed out that the country 
level socio-economic factors explained two-thirds of the variation in preventive drug use compared to only a 
third explained by individual factors (such as smoking, gender, education)[26]. Although these results are not 
in line with our findings, this knowledge needs to be appreciated for our population as well: it does show the 
between-country differences in (level of) health care availability. 
Limitations 
While ROPAC provides a unique view on global pregnancy outcome, including women from 39 countries,  the 
current distribution of countries was within a range of medium to very high HDI.  However, the range of 
country specific characteristics was sufficient to illustrate the differences between more developed countries 
and those with poorer resources. Including patients from countries categorised with a low HDI may strengthen 
   
this study, but is hard to achieve with limited availability of organised/specialised medical care in these 
countries. 
In previous studies, ethnicity was shown to influence maternal outcome[27]. In particular, non-Hispanic black 
women seem to have an increased risk of pregnancy-related mortality. ROPAC did not include demographic 
socioeconomic data at a patient level, which is why we performed the analysis at a country level. If the socio-
economic data (income, education, social status, employment, among others) were available at patient level, it 
may had been possible to find stronger relationships.  Since we performed the statistical analyses at three 
levels (patient, within centre, within country), we believe that meaningful conclusions can be drawn from our 
data. In future registries it would be desirable to collect more socioeconomic data on patient level. 
The majority of the participating centres were university or tertiary centres (86%). Unfortunately, only 75% 
responded to the question whether they were a university, community or private clinic, which is why we did 
not include this information in the statistical analysis. But it is likely that our data are derived from women 
cared for in larger centres with a specialised department for pregnancy. 
ROPAC included 6 months follow-up postpartum. However, due to large differences in follow-up availability 
between countries, it was decided not to include these results to this analysis. Follow-up at 1 week was 
available in all patients. For future research, inclusion of long-term follow-up would be favourable. Finally, the 
number of pregnancies complicated by fetal and neonatal mortality was relatively low, which hampered 
statistical modelling and conclusions should be interpreted carefully.  
This study aimed to comment on associations, rather than causal relations. It should be interpreted as a 
hypothesis generating study, and may be a starting point for future research studying for instance 
socioeconomic factors on patient level. 
Conclusion 
Socioeconomic factors were partly explainable for differences in pregnancy outcome in women with cardiac 
disease, but the main denominator was the individual’s condition, at least in countries with a medium to very 
high HDI. Raising awareness and improving access to medical resources as advocated by the World Health 
Organization, will help to improve the outcome for pregnant women, hopefully also for women with heart 
disease. 
 
   
  
   
Funding 
Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011-
2014), Amgen Cardiovascular (2009-2018), AstraZeneca (2014-2017), Bayer (2009-2018), Boehringer Ingelheim 
(2009-2016), Boston Scientific (2009-2012), The Bristol Myers Squibb and Pfizer Alliance (2011-2016), The 
Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011-2017), Edwards (2016-2019), Gedeon 
Richter Plc. (2014-2017), Menarini Int. Op. (2009-2012), MSD-Merck & Co. (2011-2014), Novartis Pharma AG 
(2014-2017), ResMed (2014-2016), Sanofi (2009-2011), SERVIER (2010-2018). The companies that support EORP 
were not involved in any part of the study or this report. 
 
Acknowledgements 
We would like to thank all ROPAC investigators listed in the Supplementary material online. Our gratitude goes 
to the EORP team for their contribution, in particular: Elin Folkesson-Lefrancq (project officer) and Viviane 
Missiamenou (data manager). To join the Registry: http://www.escardio.org/Research/Registries-&-
surveys/Observational-registry-programme/Registry-Of-Pregnancy-And-Cardiac-disease-ROPAC.  
 
Conflict of interest 
Dr. Maggioni reports grants from Novartis, Cardiorentis, and Bayer outside the submitted work. 
Dr. Tavazzi reports personal fees from Servier, CVIE Therapeutics, Cardiorentis, Boston Scientific, and 
Medtronic outside the submitted work.  
   
References 
 
1 Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, et al. Global, regional, and national levels and causes of 
maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 
2014;384:980-1004. 
2 Collaborators GBDMM. Global, regional, and national levels of maternal mortality, 1990-2015: a 
systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1775-812. 
3 Roos-Hesselink JW, Ruys TP, Stein JI, et al. Outcome of pregnancy in patients with structural or ischaemic 
heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 2013;34:657-65. 
4 van Hagen IM, Roos-Hesselink JW, Ruys TP, et al. Pregnancy in Women With a Mechanical Heart Valve: 
Data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation 
2015;132:132-42. 
5 van Hagen IM, Boersma E, Johnson MR, et al. Global cardiac risk assessment in the Registry Of Pregnancy 
And Cardiac disease: results of a registry from the European Society of Cardiology. European Journal of Heart 
Failure 2016;18:523-33. 
6 Sliwa K, Libhaber E, Elliott C, et al. Spectrum of cardiac disease in maternity in a low-resource cohort in 
South Africa. Heart 2014;100:1967-74. 
7 Soma-Pillay P, Seabe J, Sliwa K. The importance of cardiovascular pathology contributing to maternal 
death: Confidential Enquiry into Maternal Deaths in South Africa, 2011-2013. Cardiovasc J Afr 2016;27:60-5. 
8 van Hagen IM, Roos-Hesselink JW, Donvito V, et al. Incidence and predictors of obstetric and fetal 
complications in women with structural heart disease. Heart 2017. 
9 Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and 
pulmonary arterial hypertension. J Fam Plann Reprod Health Care 2006;32:75-81. 
10 Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular 
diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of 
the European Society of Cardiology (ESC). European Heart Journal 2011;32:3147-97. 
11 Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis 
and Management of Heart Failure in Adults: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the 
International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016. 
12 Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized linear mixed-
effects models. Methods in Ecology and Evolution 2013;4:133-42. 
13 https://cran.r-project.org/web/packages/lme4/index.html. 
14 Lee KS, Park SC, Khoshnood B, et al. Human development index as a predictor of infant and maternal 
mortality rates. J Pediatr 1997;131:430-3. 
15 Ignacio Ruiz J, Nuhu K, Tyler McDaniel J, et al. Inequality as a Powerful Predictor of Infant and Maternal 
Mortality around the World. PLoS One 2015:1-11. 
16 Sheldon WR, Blum J, Vogel JP, et al. Postpartum haemorrhage management, risks, and maternal 
outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. 
BJOG 2014;121 Suppl 1:5-13. 
17 Tuncalp O, Souza JP, Hindin MJ, et al. Education and severe maternal outcomes in developing countries: 
a multicountry cross-sectional survey. BJOG 2014;121 Suppl 1:57-65. 
18 Fujiwara T, Ito J, Kawachi I. Income inequality, parental socioeconomic status, and birth outcomes in 
Japan. Am J Epidemiol 2013;177:1042-52. 
19 Nkansah-Amankra S, Dhawain A, Hussey JR, et al. Maternal social support and neighborhood income 
inequality as predictors of low birth weight and preterm birth outcome disparities: analysis of South Carolina 
Pregnancy Risk Assessment and Monitoring System survey, 2000-2003. Matern Child Health J 2010;14:774-85. 
20 Bouthoorn SH, van Lenthe FJ, Gaillard R, et al. Socioeconomic inequalities in placental vascular 
resistance: a prospective cohort study. Fertil Steril 2014;101:1367-74. 
21 Singh T, Leslie K, Bhide A, et al. Role of second-trimester uterine artery Doppler in assessing stillbirth 
risk. Obstet Gynecol 2012;119:256-61. 
22 Pieper PG, Balci A, Aarnoudse JG, et al. Uteroplacental blood flow, cardiac function, and pregnancy 
outcome in women with congenital heart disease. Circulation 2013;128:2478-87. 
   
23 Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers' Lives: Reviewing maternal deaths to make 
motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the 
United Kingdom. BJOG 2011;118 Suppl 1:1-203. 
24 UN. The Millennium Development Goals report 2015. New York 2015. 
25 Sliwa K, Acquah L, Gersh BJ, et al. Impact of Socioeconomic Status, Ethnicity, and Urbanization on Risk 
Factor Profiles of Cardiovascular Disease in Africa. Circulation 2016;133:1199-208. 
26 Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the 
community in high-income, middle-income, and low-income countries (the PURE Study): a prospective 
epidemiological survey. Lancet 2011;378:1231-43. 
27 Creanga AA, Berg CJ, Syverson C, et al. Race, ethnicity, and nativity differentials in pregnancy-related 





Figure 1 Event rate for HDI categories 
Figure 2 Between country differences in outcome, unadjusted for fixed effects (A) and adjusted for fixed 
effects (B) 
Legend: Estimated unadjusted and adjusted odds ratios for a combined cardiac endpoint for each country 
compared to the average odds ratio.  Several countries do not include the 0 in their 95% confidence interval in 
the unadjusted model. But when adjusted for patient and country characteristics, the 95% confidence intervals 
of almost all countries do include 0. This means that for the vast majority of the countries, the need to account 
for random effects (patient within centre, within country) disappears when adjusting for patient and country 
characteristics. 
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